{
    "id": 16251,
    "fullName": "HGF dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "HGF dec exp indicates decreased expression of the Hgf protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3082,
        "geneSymbol": "HGF",
        "terms": [
            "HGF",
            "DFNB39",
            "F-TCF",
            "HGFB",
            "HPTA",
            "SF"
        ]
    },
    "variant": "dec exp",
    "createDate": "01/07/2016",
    "updateDate": "01/07/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3829,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, advanced medullary thyroid cancer patients with low baseline Hgf expression were more likely to display tumor reduction and prolonged progression free survival when treated with Lenvima (lenvatinib) (PMID: 26311725).",
            "molecularProfile": {
                "id": 16524,
                "profileName": "HGF dec exp"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4237,
                    "pubMedId": 26311725,
                    "title": "A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26311725"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16524,
            "profileName": "HGF dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}